Clinical trials: Human Influenza
Influenza, Human
Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines
The purpose of this 2016/17 pilot study is to improve the combination of a card-based adverse drug reaction (ADR) system and the use of routine data to collect adverse events following vaccination with seasonal influenza…
- Trial name
- NCT02893878
- Testing
- Vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 19,334 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU…
- Trial name
- NCT05568797
- Testing
- RSVPreF3 OA vaccine, FLU vaccine
- Where
- 37 sites in Belgium, Finland and 3 more
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
This study was designed to evaluate the safety and tolerability of a single dose of V114 when administered concomitantly and non-concomitantly (i.e., 30 days after) with influenza vaccine.
- Trial name
- NCT03615482
- Testing
- V114, QIV
- Where
- 45 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Background: Researchers want to know if a certain type of antibody in the blood affects whether people get influenza (the flu). They will study 2 different groups with different levels of anti-HA antibodies and expose them to the…
- Trial name
- NCT01971255
- Testing
- Ca/04/2009/H1N1r Challenge Virus
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccines
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any…
- Trial name
- FluSHED-2 (NCT03735147)
- Testing
- Live attenuated influenza vaccine (LAIV)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Response
Immune Responses Induced by Different Licensed Influenza Vaccines
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
- Trial name
- NCT00902278
- Testing
- Flulaval, Fluvirin, Fluzone
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
This study is designed to test the immunogenicity and reactogenicity of the FluarixTM/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2009-2010 season.
- Trial name
- NCT00920374
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 5 sites in Germany
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Acute Respiratory Infection
FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths.
- Conditions
- Influenza, Acute Respiratory Infection, Influenza-like Illness
- Trial name
- NCT03274310
- Testing
- Educational text messages
- Where
- United States
- Volunteers
- 1,918 people, healthy volunteers welcome
- Sponsor
- Columbia University
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Tract Infections
Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)
This trial is taking place in Los Angeles, CA at clinics within the Los Angeles Department of Health clinics. The study design is a comparative effectiveness trial design.
- Trial name
- LADHS (NCT05535777)
- Testing
- Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts
- Where
- 2 sites in United States
- Volunteers
- 246,295 people
- Sponsor
- University of California, Los Angeles
Influenza and Acute Respiratory Viral Infections
Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
The purpose of this study is: To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment of influenza and acute respiratory viral infections in children
- Trial name
- NCT02072174
- Testing
- Anaferon for Children
- Where
- 27 sites in Belarus, Russia and 1 more
- Volunteers
- 569 people
- Sponsor
- Materia Medica Holding
Influenza
Sanofi Pasteur, TIV + H1N1, Pediatric Population
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus.
- Trial name
- NCT00943202
- Testing
- Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine
- Where
- 8 sites in United States
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
The purpose of the present study is to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with vaccine GSK2340272A when co-administered with GSK Biologicals' Fluarix™ vaccine either at the time of first…
- Trial name
- NCT00968890
- Testing
- Pandemrix (Influenza vaccine GSK2340272A), Fluarix™
- Where
- 2 sites in Sweden
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the safety and immunogenicity study of GSK Biologicals' pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years.
- Trial name
- NCT01014091
- Testing
- GSK pandemic vaccine GSK2340272A
- Where
- 3 sites in Czechia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza
This research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza.
- Trial name
- NCT03410862
- Testing
- Elderberry Extract
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- michael macknin
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company